Welcome to our dedicated page for Carisma Therapeutics news (Ticker: CARM), a resource for investors and traders seeking the latest updates and insights on Carisma Therapeutics stock.
Carisma Therapeutics, Inc. (Nasdaq: CARM) is a cutting-edge clinical-stage biopharmaceutical company headquartered in Philadelphia, PA. The company is dedicated to developing transformative immunotherapies for cancer and other serious diseases using its proprietary chimeric antigen receptor macrophage (CAR-M) and monocyte cell engineering platforms.
Carisma is pioneering the use of engineered macrophages and monocytes, which are types of white blood cells essential for immune response. By harnessing these cells, Carisma aims to create innovative treatments for diseases with unmet medical needs. The company's leading product candidates include CT-0508 and CT-0525, both targeting HER2-overexpressing tumors.
CT-0508 is a CAR-M therapy currently in a Phase 1 clinical trial, marking the first time engineered macrophages are being tested in humans. It targets patients with recurrent or metastatic HER2-overexpressing solid tumors who have not responded to standard treatments. CT-0525, on the other hand, is an autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy. Recently cleared by the FDA, it has shown promising preclinical results and is expected to begin Phase 1 trials shortly.
The company's collaboration with Moderna, Inc. to develop in vivo CAR-M therapeutics highlights Carisma's commitment to innovative partnerships. This joint effort aims to leverage Moderna's mRNA and lipid nanoparticle (LNP) technologies to create new cancer treatments.
Carisma has also made significant strides in non-oncology applications. Recently, preclinical data demonstrated the efficacy of engineered macrophages in treating liver fibrosis, indicating potential for broader applications of their technology.
Financially, Carisma is robust, with $94.1 million in cash, cash equivalents, and marketable securities as of September 30, 2023. This financial stability enables the company to sustain its planned operations into the first quarter of 2025.
For more information, please visit www.carismatx.com.
Carisma Therapeutics Inc. (Nasdaq: CARM) reported financial results for Q1 2024 and highlighted recent business updates. The company announced CT-0525 as the lead product candidate for the anti-HER2 program, presented preclinical proof of concept data in liver fibrosis, and reported Regimen Level 1 data from Phase 1 sub-study utilizing CT-0508. Carisma plans to treat the first patient in the CT-0525 Phase 1 clinical study in Q2 2024 and expects to have initial data by year-end 2024. The company also reported a cash balance of $56.5 million, expected to fund operations into Q3 2025.
Carisma Therapeutics Inc. (Nasdaq: CARM) presented groundbreaking preclinical data at ASGCT 2024, showcasing the efficacy of engineered macrophages in reducing liver fibrosis. The therapy demonstrated significant reductions in fibrosis in liver and lung models, offering promising solutions for metabolic dysfunction-associated diseases. Carisma plans to nominate a development candidate for its liver fibrosis program in early 2025.
Carisma Therapeutics Inc. (Nasdaq: CARM) is set to participate in The Citizens JMP Life Sciences Conference. The company, a clinical-stage biopharmaceutical firm specializing in innovative immunotherapies, will have its President and CEO, Steven Kelly, engage in a fireside chat on May 13th at 12:00 pm ET. The event will be webcasted and archived on the Investor Relations webpage.
Carisma Therapeutics Inc. (Nasdaq: CARM) has appointed Dr. Eugene P. Kennedy as the Chief Medical Officer. Dr. Kennedy, with over 15 years of experience in clinical and industry settings, will oversee Carisma's clinical development, regulatory, and medical affairs functions. His expertise in oncology and immuno-oncology is expected to positively impact the organization and advance their clinical program and pipeline.
FAQ
What is the current stock price of Carisma Therapeutics (CARM)?
What is the market cap of Carisma Therapeutics (CARM)?
What is Carisma Therapeutics' core focus?
What are Carisma Therapeutics' leading products?
What recent achievements has Carisma Therapeutics made?
Who are Carisma Therapeutics' key partners?
Where is Carisma Therapeutics headquartered?
How is Carisma Therapeutics financially positioned?
What is CT-0508?
What is CT-0525?
What types of diseases is Carisma Therapeutics targeting?
How can I get more information about Carisma Therapeutics?
